A Single-Arm, Open-Label, Multi-Center, Phase I Study of YY-20394 in Patients With Advanced Solid Tumors
Latest Information Update: 07 Jul 2021
At a glance
- Drugs Linperlisib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Intestinal cancer; Liver cancer; Lung cancer; Malignant thymoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Yingli Pharmaceutical
Most Recent Events
- 08 Jun 2021 Results (Data cut off 28 Dec 2020, n=70) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2021 Results presented in the Yingli Pharma Media Release.
- 03 Jun 2021 According to a Yingli Pharma media release, data from this trial will be presented at the at the American Society for Clinical Oncology 2021 Annual Meeting.